Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. United Kingdom
  4. London Stock Exchange
  5. GlaxoSmithKline plc
  6. News
  7. Summary
    GSK   GB0009252882

GLAXOSMITHKLINE PLC

(GSK)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Pfizer's Dormitzer Leaves For GlaxoSmithKline's Vaccine Research: Financial Times

11/30/2021 | 08:15am EST


© MT Newswires 2021
All news about GLAXOSMITHKLINE PLC
01/25Trian expected to revive its P&G playbook with Unilever
RE
01/25GlaxoSmithKline plc - FDA approves Nucala 40 mg prefilled syringe for children with sev..
AQ
01/25UNILEVER'S SOAP OPERA : M&A, job cuts and grumpy investors
RE
01/25EUROPEAN MIDDAY BRIEFING - Stocks Push Higher But -2-
DJ
01/25Unilever to Restructure, Cut 1,500 Jobs Amid Shareholder Pressure -- Update
DJ
01/25After rocky start to year, Unilever axes 1,500 managers
RE
01/25GLAXOSMITHKLINE : JP Morgan remains Neutral
MD
01/25EMEA MORNING BRIEFING : Stocks to Rise After Wall -2-
DJ
01/24Unilever to Lay Off Thousands of Managers After Failed GSK Consumer Health Bid
MT
01/24U.S. FDA limits use of Regeneron, Lilly COVID-19 antibody treatments
RE
More news
Analyst Recommendations on GLAXOSMITHKLINE PLC
More recommendations
Financials
Sales 2021 33 905 M 45 607 M 45 607 M
Net income 2021 4 080 M 5 488 M 5 488 M
Net Debt 2021 20 842 M 28 036 M 28 036 M
P/E ratio 2021 20,3x
Yield 2021 4,90%
Capitalization 82 109 M 111 B 110 B
EV / Sales 2021 3,04x
EV / Sales 2022 2,82x
Nbr of Employees 94 066
Free-Float 92,2%
Chart GLAXOSMITHKLINE PLC
Duration : Period :
GlaxoSmithKline plc Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends GLAXOSMITHKLINE PLC
Short TermMid-TermLong Term
TrendsNeutralBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 22
Last Close Price 1 631,80 GBX
Average target price 1 753,59 GBX
Spread / Average Target 7,46%
EPS Revisions
Managers and Directors
Emma N. Walmsley Chief Executive Officer & Executive Director
Iain James Mackay Chief Financial Officer & Executive Director
Jonathan Richard Symonds Non-Executive Chairman
Karenann K. Terrell Chief Digital & Technology Officer
Hal V. Barron Executive Director & Chief Scientific Officer
Sector and Competitors
1st jan.Capi. (M$)
GLAXOSMITHKLINE PLC1.57%109 587
JOHNSON & JOHNSON-2.01%441 302
ROCHE HOLDING AG-8.68%304 745
PFIZER, INC.-11.02%294 900
ABBVIE INC.-1.71%235 287
ELI LILLY AND COMPANY-13.31%217 093